Fig 6.
Pyronaridine reduces infection against mouse-adapted SARS-CoV-1 in vivo. Wild type 8- to 10-week-old BALB/c mice were treated with pyronaridine (oral administration) daily at the indicated concentrations starting 12 h before infection. Mice (n = 5 per group) were intranasally inoculated with 1 × 105 PFU per mouse of SARS-CoV-1 mouse-adapted strain (MA-15). (A–E) Mice were weighed daily (A), lungs were analyzed for viral titer 2 and 4 days after infection by plaque assay (B), or fixed in 4% paraformaldehyde for H&E staining (C) and quantified for lung inflammation scoring (D). Mice were monitored and given a clinical score for disease severity daily (E). n = 5 mice per group. Mean ± SD is shown. *P < 0.05, **P < 0.01, and ***P < 0.001, using two-way analysis of variance with Tukey’s multiple comparison tests on log-transformed virus titers. The red asterisks are compared to virus-only group.